Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCVRx Inc

CVRx Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.70015 USD 0.00 ( 0.70%)
Last update at 2026-11-11T21:00:00Z
VOLUME
350400
Market Cap
190.50M

Momentum Score

…

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.70
Low
0.74
High
52 Week Price Range
4.30
Low
11.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

CVRx Inc develops Barostim, an implantable neuromodulation system that stimulates carotid baroreceptors to modulate autonomic tone in patients with chronic heart failure and conducts clinical, regulatory and commercialization activities. Long-term growth drivers include clinical evidence and label expansion, reimbursement progress, international adoption and partnerships, which may benefit investors since the technology addresses an unmet therapeutic need in heart failure.
Material risks include limited commercial traction, dependence on further positive clinical and regulatory results, reimbursement uncertainty, competition from drug and device therapies and potential need for additional capital.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.70
Dividend Yield
-
Revenue TTM
56.65M
Revenue Per Share
2.17
Gross Profit TTM
48.34M
Debt / Equity
1.29
ROE
-96.59%
Net Debt
-24.92M
ROCE
-56.04%
Diluted EPS TTM
-2.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -53.32M -59.91M -41.05M -41.32M -42.99M
Net income -53.31M -59.97M -41.20M -41.43M -43.08M
Selling general administrative 88.47M 91.32M 61.60M 50.05M 27.86M
Gross profit 48.34M 42.96M 33.04M 17.47M 9.40M
Reconciled depreciation 0.76M 0.62M 0.52M 0.41M 0.17M
Ebit - -55.51M -43.10M -42.53M -25.97M
Ebitda -51.27M -54.89M -43.10M -41.15M -40.77M
Depreciation and amortization - 0.62M 0.52M 1.37M -14.80M
Non operating income net other - - - 1.37M -14.80M
Operating income -51.27M -59.49M -43.10M -42.53M -25.97M
Other operating expenses 107.92M 110.78M 82.40M 65.00M 39.00M
Interest expense 5.83M 4.40M 1.80M 0.17M 2.22M
Tax provision -0.02M 0.06M 0.14M 0.11M 0.09M
Net interest income -5.83M -4.40M -1.39M -0.17M -2.22M
Income tax expense 0.02M 0.06M -0.15M 0.11M 0.09M
Total revenue 56.65M 51.29M 39.30M 22.47M 13.04M
Total operating expenses 99.61M 102.45M 76.14M 60.00M 35.36M
Cost of revenue 8.31M 8.33M 6.26M 5.00M 3.64M
Total other income expense net -2.06M -0.42M 2.05M 1.21M -17.02M
Net income from continuing ops -53.31M -59.97M -42.57M -41.43M -43.08M
Net income applicable to common shares - - - -41.43M -43.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 104.79M 133.41M 115.23M 124.94M 152.55M
Other current assets 3.07M 2.50M 2.99M 4.22M 2.58M
Total liab 65.47M 62.36M 39.28M 15.76M 6.59M
Total stockholder equity 39.32M 71.06M 75.95M 109.18M 145.96M
Other current liab 9.48M 7.76M 5.98M 6.15M 5.40M
Common stock 0.26M 0.25M 0.21M 0.21M 0.20M
Capital stock 0.26M 0.25M 0.21M 0.21M 0.20M
Retained earnings -590.65M -537.35M -477.38M -436.18M -394.75M
Other liab - - - 0.81M 0.68M
Other assets - - - 0.03M 0.03M
Cash 75.71M 105.93M 90.57M 106.19M 142.07M
Total current liabilities 13.32M 10.76M 7.86M 8.09M 5.91M
Current deferred revenue - - -0.23M - -
Net debt -24.92M -55.50M -59.96M -99.11M -142.07M
Short term debt - 0.28M 0.23M 0.22M -
Short long term debt total 50.79M 50.43M 30.61M 7.09M -
Other stockholder equity 629.92M 608.35M 553.33M 545.36M 388.16M
Property plant equipment - - - 1.70M 1.43M
Total current assets 101.65M 129.81M 112.09M 122.88M 151.10M
Net tangible assets - - - 109.18M 145.96M
Net receivables 10.66M 9.27M 7.55M 5.50M 2.56M
Long term debt 49.51M 49.27M 29.22M 6.75M -
Inventory 12.21M 12.11M 10.98M 6.96M 3.88M
Accounts payable 3.83M 2.58M 1.88M 1.72M 0.51M
Accumulated other comprehensive income -0.20M -0.21M -0.21M -0.21M -0.20M
Common stock total equity - - - 0.21M 0.20M
Retained earnings total equity - - - -436.18M -394.75M
Non currrent assets other 0.03M 0.03M 0.03M 0.03M 0.03M
Non current assets total 3.15M 3.60M 3.14M 2.06M 1.45M
Capital lease obligations 0.99M 1.16M 1.39M 0.12M -
Long term debt total - - - 6.75M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -1.36M -0.50M -0.69M -1.18M
Change to liabilities - - - 2.08M 2.21M
Total cashflows from investing activities -0.58M -1.36M -0.59M -0.69M -1.18M
Net borrowings 0.00M 20.00M 22.50M 6.72M -21.30M
Total cash from financing activities 10.52M 55.87M 23.98M 7.49M 111.88M
Change to operating activities - - - -0.76M 0.21M
Net income -53.31M -59.97M -41.20M -41.43M -43.08M
Change in cash -30.23M 15.36M -15.62M -35.88M 82.96M
Begin period cash flow 105.93M 90.57M 106.19M 142.07M 59.11M
End period cash flow 75.71M 105.93M 90.57M 106.19M 142.07M
Total cash from operating activities -40.17M -39.14M -39.02M -42.68M -27.73M
Issuance of capital stock 8.97M 32.52M 0.00M 0.00M 133.16M
Depreciation 0.76M 0.62M 0.52M 0.41M 0.17M
Change to inventory -0.10M -1.12M -4.03M -3.08M -0.54M
Change to account receivables -1.40M -1.72M -2.05M -2.94M -1.28M
Sale purchase of stock - - - 0.77M -0.00M
Other cashflows from financing activities 10.52M 3.35M 1.48M 7.31M 0.02M
Change to netincome - - - 3.89M 16.53M
Capital expenditures 0.58M 1.36M 0.59M 0.69M 1.18M
Change receivables - - - -2.94M -1.28M
Cash flows other operating - - - -1.63M -1.98M
Cash and cash equivalents changes - - - -35.87M 82.97M
Change in working capital 1.00M 0.95M -4.80M -5.57M -1.58M
Stock based compensation 11.05M 19.05M 6.30M 3.89M 1.91M
Other non cash items 0.33M 0.20M 0.16M 0.03M 0.23M
Free cash flow -40.75M -40.51M -39.61M -43.36M -28.91M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CVRX
CVRx Inc		 0.00
0.70%		 0.70 - - 3.36 4.84 2.92 -1.31
ABT
Abbott Laboratories		 -1.17
1.06%		 109.29 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.02
0.02%		 101.61 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -5.50
1.70%		 318.79 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.30
0.63%		 48.57 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

CVRx Inc

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

9201 West Broadway Avenue, Minneapolis, MN, United States, 55445

763 416 2840

https://www.cvrx.com

223

Name Title Year Born
Mr. Nadim Yared CEO, Pres & Director 1968
Mr. Jared Oasheim Chief Financial Officer 1983
Mr. Paul Verrastro Chief Marketing & Strategy Officer 1963
Mr. Paul Pignato VP of Operations NA
Mr. Craig Palmer Sr. VP of US Sales 1977
Mr. Kevin Hykes President, CEO & Director 1966
Mr. Jared Oasheim Chief Financial Officer 1984
Mr. Paul Pignato Vice President of Operations NA
Ms. Jonelle R. Burnham Vice President & General Counsel 1971
Mr. Craig Palmer Senior Vice President of US Sales 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…